No improvement on second-line treatment with tisagenlecleucel in patients with DLBCL
Patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to first-line therapy or relapse within one year following first-line therapy have a poor prognosis. Presented by Michael Bishop, this MEDtalk summarize the results of the BELINDA trial. The trial randomizes patients in two arms to investigate effects of tisagenlecleucel, a CD19-directed CAR T-cell therapy, as second-line treatment. Unfortunately, BELINDA did not meet its primary end point, as second-line tisagenlecleucel did not improve event-free survival (EFS) compared with standard of care (SOC). However, more learnings to help design further trials in patients were derived from the trial.
Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.